Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference By: Alto Neuroscience, Inc. via Business Wire February 27, 2024 at 08:00 AM EST Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET. The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227427565/en/Contacts Investor Contact: Nick Smith investors@altoneuroscience.com Media Contact: Jordann Merkert media@altoneuroscience.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference By: Alto Neuroscience, Inc. via Business Wire February 27, 2024 at 08:00 AM EST Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET. The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227427565/en/Contacts Investor Contact: Nick Smith investors@altoneuroscience.com Media Contact: Jordann Merkert media@altoneuroscience.com
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024, at 1:30 pm ET. The presentation will also be available via live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available for 90 days following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X. View source version on businesswire.com: https://www.businesswire.com/news/home/20240227427565/en/
Investor Contact: Nick Smith investors@altoneuroscience.com Media Contact: Jordann Merkert media@altoneuroscience.com